---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004669"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:05:20.008410+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics Q2 net loss $13.1M; CTX-009 BTC trial enrollment completed, top-line data Q1 2025

## Summary
- Net loss of $13.1M ($0.10 per share) for Q2 2024 vs $11.3M loss in Q2 2023.
- Cash and marketable securities $146M as of June 30, 2024; cash runway into Q1 2027.
- Completed enrollment (n=150) in COMPANION-002 Phase 2/3 trial of CTX-009 in BTC; top-line data expected Q1 2025.
- Stage 1 of COMPANION-003 in CRC showed ORR 5%, median PFS 3.9 months, median OS 10.2 months; designing second-line DLL4+ study.
- Discontinuing CTX-471 + KEYTRUDA combo due to cytokine suppression; planning Phase 2 monotherapy with new biomarker.

## SEC filing metadata
- accession: 0001171843-24-004669
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184324004669/0001171843-24-004669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184324004669/f8k_081024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004669
- JSON: https://secwatch.observer/filing/0001171843-24-004669.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004669.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.